1,417K shares changed hands on Friday. Overall, volume was up 106.26% over the stocks normal daily volume.
There has been some buying and selling insider activity on Bruker Corporation (NASDAQ:BRKR) recently. Ingen Chris Van, Director reported the sale of 19,900 shares. The shares were purchased at an average price of $28.03. Van now owns $128,293 of the stock per the Form 4 SEC filing. Mark Munch, Exec VP disclosed the sale of 73,724 shares of BRKR stock. The shares were sold on June 8th for an average price of $27.62. The Exec VP now owns $1,696,559 of the stock according to the SEC filing.
CEO Frank H. Laukien disclosed the purchase of 3,200 shares of (BRKR). The shares were purchased at an average price of $26.13. The CEO now owns $987,427,903 of the stock per the Form 4 SEC filing.
Here are a few other firms who have also updated their positions. As of the end of the quarter Marshall Wace, Llp had acquired 9,065 shares growing its stake by 6.0%. The value of the investment in (BRKR) went from $3,485,000 to $4,657,000 a change of 33.6% quarter to quarter. As of quarter end Marshall Wace North America L.p. had sold a total of 28,370 shares trimming its position 32.6%. The value in dollars decreased from $2,003,000 to $1,703,000 a change of $300,000 since the last quarter.
Cadence Capital Management LLC cut its holdings by shedding 27,455 shares a decrease of 37.8% in the quarter. Cadence Capital Management LLC claims 45,209 shares with a value of $1,304,000. The value of the position overall is down by 35.9%. As of quarter end Federated Investors Inc /pa/ had disposed of 686 shares trimming its holdings by 1.6%. The value of the investment in Bruker Corporation increased from $1,007,000 to $1,225,000 increasing 21.6% quarter over quarter.
On July 13 the company was downgraded to “Underperform” from “Outperform” in an announcement from Wells Fargo. On December 14, 2016 JP Morgan maintained a price target of $20.00 but downgraded the company from Neutral to Underweight.
On December 14 the stock rating was downgraded from “Neutral” to “Underweight” and a price target of $20.00 was set by JP Morgan. On November 10, 2016 Leerink Swann started coverage by announcing an initial rating of “Market Perform”.
Equity analyst BTIG Research started covering BRKR with an initial rating of “Neutral”. On May 5 the company was downgraded from “” to “Neutral” by analysts at BTIG Research.
The company is down by -2.07% since yesterday’s close of $28.47. Bruker Corporation also recently declared a dividend for shareholders which was paid on Friday the 23rd of June 2017. The dividend payment was $0.040 per share for the quarter which is $0.16 annualized. This dividend represents a yield of $0.56. The ex-dividend date was set for Thursday the 1st of June 2017.
Shares are trading at $27.88 which is just a bit below $28.70, the 50 day moving average and a bit higher than the 200 day moving average of $25.43. The 50 day moving average went down $-0.82 or -2.87% and the 200 day average moved up $2.45.
The P/E ratio is currently 29.60 and the market value is 4.45B. As of the last earnings report the EPS was $0.94 and is estimated to be $1.10 for the current year with 159,768,000 shares outstanding. Next quarter’s EPS is expected be $0.43 and the next full year EPS is projected to be $1.24.
Bruker Corporation, launched on February 4, 2000, is a developer, manufacturer and distributor of scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. The Business’s segments include Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST). The Business’s products address the evolving needs of an array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research. Its technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas and liquid chromatography triple quadrupole mass spectrometry technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology, fluorescence optical microscopy and infrared and Raman molecular spectroscopy technologies. It also develops, manufactures and distributes a range of field analytical systems for chemical, biological, radiological, nuclear and explosives (CBRNE) detection. It also develops, manufactures and markets high and low temperature superconducting materials and devices based primarily on metallic low temperature superconductors..